{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:44:11Z","timestamp":1784817851537,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:13:36Z","timestamp":1772036016000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs"],"prefix":"10.1053","volume":"62","author":[{"given":"Elizabeth","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1053\/j.seminhematol.2026.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discovery"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0003","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0004","unstructured":"FDA. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry 2018 [accessed 10.15.2025] https:\/\/www.fda.gov\/media\/71195\/download."},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0005","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]","year":"2016"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.002_bib0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/fon-2022-0932","article-title":"Overall and complete response rates as potential surrogates for overall survival in relapsed\/refractory multiple myeloma","volume":"19","author":"Daniele","year":"2023","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0007","unstructured":"FDA. Table of surrogate endpoints that were the basis of drug approval or licensure. 2025 Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure."},{"issue":"19","key":"10.1053\/j.seminhematol.2026.02.002_bib0008","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-24-1086","article-title":"FDA approval summary: asciminib for ph+ CML in chronic phase treated with two or more tyrosine kinase inhibitors and for the T315I mutation","volume":"30","author":"Pamuk","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0009","unstructured":"FDA, Guidance for industry: expedited programs for serious conditions - drugs and biologics. 2014."},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0010","unstructured":"Gilead, Final abbreviated clinical study report, a phase 3 randomized double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia. 2016."},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0011","unstructured":"Gilead, Final abbreviated clinical study report, a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent Non-Hodgkin lymphomas. 2016."},{"issue":"18","key":"10.1053\/j.seminhematol.2026.02.002_bib0012","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1182\/bloodadvances.2024013236","article-title":"CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma","volume":"8","author":"Zinzani","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0013","unstructured":"G Dharmamoorthy, et al., A review on FDA approval of lymphoma drug Ukoniq (Umbralisib) and its withdrwal due to safety concerns. 2022."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.002_bib0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2021-145757","article-title":"Final overall survival results from BELLINI, a phase 3 study of Venetoclax or Placebo in combination with Bortezomib and Dexamethasone in relapsed\/refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.002_bib0016","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.02.002_bib0017","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.002_bib0018","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in Myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0019","unstructured":"Administration., U.S.F.A.D. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment\u2014guidance for industry. 2020."},{"issue":"11","key":"10.1053\/j.seminhematol.2026.02.002_bib0020","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.002_bib0021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0022","series-title":"Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval","year":"2026"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood,"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.02.002_bib0024","doi-asserted-by":"crossref","first-page":"e7310","DOI":"10.1002\/cam4.7310","article-title":"Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults","volume":"13","author":"Yu","year":"2024","journal-title":"Cancer Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.02.002_bib0025","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.02.002_bib0026","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.002_bib0027","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.002_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41375-024-02483-5","article-title":"Surrogate endpoints in mature B-cell neoplasms \u2013 meaningful or misleading?","volume":"39","author":"Simon","year":"2025","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.002_bib0030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.002_bib0031","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2025-343","article-title":"Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials","volume":"146","author":"Tettero","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1078-0432.CCR-23-2690","article-title":"Novel approach to accelerate lung cancer research: lung-MAP and the potential of public-private partnerships","volume":"30","author":"Herbst","year":"2024","journal-title":"Clin Cancer Res,"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.002_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013Guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.002_bib0034","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"New Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.02.002_bib0035","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.002_bib0036","doi-asserted-by":"crossref","first-page":"2000.1","DOI":"10.1182\/blood-2024-200210","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)- Master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0037","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"New Engl J Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.02.002_bib0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood-2025-248","article-title":"A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)","volume":"146","author":"Kazandjian","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.02.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaf322","article-title":"De-escalation trials do not always need to be noninferiority: a case for superiority design de-escalation trials in oncology","author":"Gyawali","year":"2025","journal-title":"J National Cancer Inst"},{"issue":"29","key":"10.1053\/j.seminhematol.2026.02.002_bib0040","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.002_bib0042","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.02.002_bib0043","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41416-022-01937-w","article-title":"Interpreting the results of noninferiority trials\u2014A review","volume":"127","author":"Cuzick","year":"2022","journal-title":"Brit J Cancer"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:35Z","timestamp":1778728055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000041"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRD as an early endpoint in myeloma and other hematologic malignancies: Implication for ongoing and future study designs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}